Psychedelics
August 15, 2026
Khaleel Rajwani
Recent interdisciplinary scholarship has demonstrated how systemic racism, racialized mental health disparities, and histories of colonial and biomedical violence shape psychedelic experiences, therapeutic outcomes, and processes of integration. Emerging literature has foregrounded concerns including racial underrepresentation in research, the violent legacy of the War on Drugs, systemic racism...
Canadian Journal of Bioethics
2026
Khaleel Rajwani
1 citation
L’exclusion de tous les patients ayant des antécédents personnels ou familiaux de psychose de la recherche sur les thérapies psychédéliques soulève d’importantes questions éthiques. Après avoir résumé l’imbrication et la séparation historiques de la recherche sur les psychédéliques et la psychose dans la psychiatrie occidentale, j’aborde certaines des raisons cliniques et socioculturelles...
Philosophical Psychology
September 8, 2025
Mina Caraccio, Katherine Cheung, Sebastian Porsdam Mann et al.
3 citations
The current revival of interest in classic psychedelics and other psychoactives such as ketamine and MDMA, coupled with changes to their regulatory status in many jurisdictions, necessitates rigorous ethical guidelines both within and beyond clinical and scientific contexts. This paper examines crucial ethical, philosophical, and policy considerations needed to ensure psychedelic use across...
The Lancet Child & Adolescent Health
September 2, 2025
Khaleel Rajwani, Edward Jacobs, Lori Bruce et al.
6 citations
The potential use of psychedelic-assisted therapy for adolescents with mental illness has sparked both interest and concern. Modern psychedelic research has focused on adults, and adolescents younger than 18 years are typically excluded due to ethical and legal challenges. To explore whether adolescents have been included in 21st century psychedelic research, we conducted a scoping review of...
Wellcome Open Research
July 8, 2025
Khaleel Rajwani, Melanie Almonte, F. Feroz et al.
2 citations
Background Recent years have seen renewed clinical interest in the therapeutic potential of classical psychedelics, such as psilocybin, LSD, DMT, and mescaline. While modern studies have focused on adult populations, adolescents under 18 are routinely excluded due to regulatory, legal, and ethical challenges. Although there exists observational data and historical studies from 1959 to 1974...
The American Journal of Bioethics
January 2, 2025
Khaleel Rajwani
2 citations
Cohen and Marks (2025) discuss medical exceptionalism within the context of psychedelic access pathways, noting that the medical model is just one of many possible approaches to using, understandin...
American Journal of Bioethics
May 2, 2024
Edward Jacobs, Brian D. Earp, Paul S. Appelbaum et al.
29 citations
The first Hopkins-Oxford Psychedelic Ethics (HOPE) workshop convened to discuss ethical matters relating to psychedelics in August 2023 at the University of Oxford.The organizers (BDE, DBY, EJ) aim...
Canadian Journal of Bioethics
December 7, 2023
Khaleel Rajwani
6 citations
In light of high-profile cases of sexual assault and other unethical conduct by therapists, recent clinical research involving psychedelic drugs has generally mandated the video recording of therapy sessions. In this paper, I address a gap in the literature by investigating ethical issues related to video recording in the unique context of psychedelic therapy sessions. I begin by summarizing...
Canadian Journal of Bioethics
2022
Khaleel Rajwani
9 citations
Recent evidence shows significant potential for therapies involving psychedelic substances such as psilocybin and MDMA to improve clinical outcomes for patients experiencing various mental disorders. However, research to date focuses almost exclusively on adults. I argue that adolescents should be included in research into psychedelic therapies. First, I demonstrate the pressing need for novel...